(MedPage Today) -- After a day of deliberations, an FDA advisory committee concluded that the agency should approve Invokana (canagliflozin), a novel agent for type 2 diabetes. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment